JuanCarlos MD - Valneva SE Chief Board

All Insiders . USA . 
Stock . Valneva SE . Stakeholders . Insider . JuanCarlos MD
INRLF Stock  USD 4.52  0.25  5.24%   

Insider

JuanCarlos MD is Chief Board of Valneva SE
Age 52
Phone33 2 28 07 37 10
Webhttps://valneva.com

Valneva SE Management Efficiency

The company has return on total asset (ROA) of (0.185) % which means that it has lost $0.185 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.8614) %, meaning that it generated substantial loss on money invested by shareholders. Valneva SE's management efficiency ratios could be used to measure how well Valneva SE manages its routine affairs as well as how well it operates its assets and liabilities.
Valneva SE has accumulated 50.73 M in total debt with debt to equity ratio (D/E) of 1.43, which is about average as compared to similar companies. Valneva SE has a current ratio of 1.13, suggesting that it may not be capable to disburse its financial obligations in time and when they become due. Debt can assist Valneva SE until it has trouble settling it off, either with new capital or with free cash flow. So, Valneva SE's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Valneva SE sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Valneva to invest in growth at high rates of return. When we think about Valneva SE's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Delin RenViva Biotech Holdings
63
Guy MDIdorsia
67
Chen MaoViva Biotech Holdings
61
Tobias KramerArjo AB
N/A
Christian StentoftArjo AB
39
Ying MBAViva Biotech Holdings
60
Brian LevinkindWashTec AG
57
Chris EricksenWashTec AG
N/A
Anurag RelanPharming Group NV
51
Joacim LindoffArjo AB
50
Shane SabatinoWashTec AG
N/A
Marc MDBasilea Pharmaceutica AG
59
Jeroen WakkermanPharming Group NV
54
Christoph BossIdorsia
54
Damian HellerBasilea Pharmaceutica AG
57
Eva FongWashTec AG
N/A
Lutz WevelsiepBasilea Pharmaceutica AG
N/A
Zhixiong YeViva Biotech Holdings
63
Peer SchroderBasilea Pharmaceutica AG
N/A
Jonas CederhageArjo AB
52
Xueheng ChengViva Biotech Holdings
67
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. The company was founded in 1998 and is headquartered in Saint-Herblain, France. Valneva Se is traded on OTC Exchange in the United States. Valneva SE [INRLF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC).

Management Performance

Return On Equity-1.86
Return On Asset-0.18

Valneva SE Leadership Team

Elected by the shareholders, the Valneva SE's board of directors comprises two types of representatives: Valneva SE inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Valneva. The board's role is to monitor Valneva SE's management team and ensure that shareholders' interests are well served. Valneva SE's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Valneva SE's outside directors are responsible for providing unbiased perspectives on the board's policies.
Dipal Patel, Chief Board
Frederic Jacotot, Vice President General Counsel, Member of the Executive Committee
Laetitia BachelotFontaine, Investor Relations Manager
JuanCarlos MD, Chief Board
Thomas Lingelbach, Chairman of the Management Board and Executive Board, Co-President CEO
Gerald Strohmaier, VP Resource
Peter Buhler, CFO Member
Franck MBA, Chief Gen
Joshua Drumm, VP Relations
Perry Celentano, Interim Officer

Valneva Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Valneva SE a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-1.86
Return On Asset-0.18
Profit Margin0.17 %
Operating Margin0.06 %
Current Valuation880.26 M
Shares Outstanding138.22 M
Shares Owned By Insiders17.56 %
Shares Owned By Institutions21.62 %
Price To Earning(4.57) X
Price To Book5.63 X

Currently Active Assets on Macroaxis

VOOVanguard SP 500
XLKTechnology Select Sector
XLVHealth Care Select
QQQInvesco QQQ Trust
XLCCommunication Services Select

Other Information on Investing in Valneva Pink Sheet

Valneva SE financial ratios help investors to determine whether Valneva Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Valneva with respect to the benefits of owning Valneva SE security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY